Disease relevance of CYP4V2

• Fifty-nine patients with nonmetastatic classic intramedullary osteosarcoma were randomized; 32 received postoperative adjuvant chemotherapy consisting of high-dose methotrexate, Adriamycin (Adria Laboratories, Columbus, OH), and BCD (bleomycin, cytoxan, actinomycin D), and 27 patients received no adjuvant chemotherapy [1].
• In HIV uninfected individuals with triple BCD hepatitis, hepatitis D virus (HDV) appears to be the dominant virus [2].
• Truncated derivatives of FnBPA, presenting either the fibrinogen-binding A domain or the fibronectin-binding BCD region, each promoted platelet activation when expressed on the surface of S. aureus or Lactococcus lactis, indicating two distinct mechanisms of activation [3].
• In this sample of 140 patients undergoing hepatic resection to remove cancerous tissue, hypercoagulation was the most common postoperative BCD; in ten patients, this complication led to hepatic failure and hepatic coma [4].
• The synthesis and structural analysis, involving X-ray crystallographic, nuclear magnetic resonance, and computational studies of four diastereomers of the common western BCD diarylether macrocycle of the complestatins, a family of HIV entry inhibitors, has been achieved exploiting a ruthenium-promoted intramolecular S(N)Ar reaction [5].

Psychiatry related information on CYP4V2

• Those who met our BCD criteria had significantly higher PTSD symptom scores than those who did not [6].

High impact information on CYP4V2

• The CYP4V2 gene, transcribed from 11 exons spanning 19 kb, is expressed widely [7].
• Homology to other CYP450 proteins suggests that CYP4V2 may have a role in fatty acid and steroid metabolism, consistent with biochemical studies of patients with BCD [7].
• The BCD region of chromosome 4q35.1 was refined to an interval flanked centromerically by D4S2924 by linkage and haplotype analysis; mutations were found in the novel CYP450 family member CYP4V2 in 23 of 25 unrelated patients with BCD tested [7].
• The more intensive preoperative regimen consisted of two courses of cisplatin (CDDP) and doxorubicin (DOX) in addition to the usual preoperative regimen of high-dose methotrexate (HD MTX) and bleomycin, cyclophosphamide, and dactinomycin (BCD) [8].
• Preoperative chemotherapy consisted of four courses of high-dose methotrexate (MTX) and one course of bleomycin, cyclophosphamide, and dactinomycin (BCD) [9].

Chemical compound and disease context of CYP4V2

• Using high-dose methotrexate, doxorubicin, and cisplatinum (or BCD) for adjuvant chemotherapy in osteosarcoma of the extremities, we achieved 8-year metastasis-free survival rates of 60-70% [10].

Biological context of CYP4V2

• The results showed that the BCD gene expression was not related to the phenotypes of SMA [11].
• In contrast, four phylogenies showed topologies of the form (A) (BCD) with statistically significant support [12].
• Radical and palladium-catalyzed cyclizations to cyclobutenes: an entry to the BCD ring system of penitrem D [13].
• Hydrolysis of the major isomer gave the dione 27', a model for the BCD ring system of pentacyclic triterpenes [14].
• However, in those patients not having a good effect of preoperative chemotherapy on the primary tumor, HDMTX with CFR was subsequently deleted from their postoperative chemotherapy and they were placed on a regimen containing cisplatinum at the dose of 120mg/M2 with mannitol diuresis combined with Adriamycin in addition to BCD (regimen A) [15].

Anatomical context of CYP4V2

• To evaluate the effects of the BCD gene expression on the phenotypes of SMA, we examined lymphocyte mRNA from 9 SMA patients lacking the SMN gene, 10 asymptomatic parents, and 15 control subjects [11].
• Three patients died of septicemia during chemotherapy-induced bone-marrow depression following treatment with adriamycin or the combination of bleomycin, cyclophosphamide, and dactinomycin (BCD) [16].
• Significant correlations between axial trunk rotation and Cobb-angle measurements were observed in the thoracic region (MTI, r = .80, df = 10, P less than .005; BCD, r = .70, df = 10, P less than .025; SCOL, r = .59, df = 10, P less than .025) but were not found within the lumbar region (MTI, r = .42; BCD, r = .17; SCOL, r = .20) [17].
• However, the degree of B and NK cell depletion was dependent on the method: specific TCD resulted in low BCD (under 0.5 log), whereas CCE or CD34 positive purging gave a BCD of greater than 1 log [18].

Associations of CYP4V2 with chemical compounds

• All of these patients received intensive chemotherapy that included high-dose methotrexate; doxorubicin; and bleomycin, cyclophosphamide, and dactinomycin (BCD) [19].
• Those in the study arm received a preoperative chemotherapy consisting of high-dose methotrexate (HDMTX) and the triple drug combination of bleomycin, cyclophosphamide, and dactinomycin (BCD) and were switched to DOX/CPDD postoperatively in case of poor response [20].
• There was no difference in CDF rates in the patients receiving BCD versus CPL or receiving interferon versus no interferon [21].
• DOX/CPDD was used besides HDMTX for initial treatment in the control arm, and BCD alternatively with CPDD/ifosfamide (IFO) for postoperative salvage treatment [20].
• FnBPA-promoted platelet activation is mediated by fibrinogen and fibronectin bridges between the A domain and the BCD domains, respectively, to the low affinity form of the integrin GPIIb/IIIa on resting platelets [3].

Other interactions of CYP4V2

• The 11 exons of the CYP4V2 gene were amplified from genomic DNA of patients by polymerase chain reaction and then sequenced [22].

Analytical, diagnostic and therapeutic context of CYP4V2

• The coding region (including the intron-exon boundary) of CYP4V2 was amplified by polymerase chain reaction (PCR) [23].
• The histologic grade of regression of 50 osteosarcomas after polychemotherapy - according to the protocol study, COSS 80 - was classified on a six-stage regression scale; 56% of all patients responded well to chemotherapy regression grades I, II, and III and no significant difference between BCD- and CPL-treated patients could be found [24].
• Five stable patients on AFB were switched to bicarbonate hemodialysis (BCD) for a 2-week period using the same AN69 membrane dialyzer [25].
• The BCD conjugates described in the present study represent suitable candidates for biotechnological applications, e.g. in analyses using biosensors, which might benefit from increased storage stability and amine oxidation at high temperatures [26].
• Five blood cardioplegia delivery systems (Gish Straight Shot, Sorin BCD Advanced, Avecor MYOtherm, Baxter-Bentley HE-30, and Baxter-Bentley HE-30 Gold) were evaluated with respect to ease of rapid priming, coefficient of heat exchange, pressure drop, bubble trap capacity, and priming volume [27].

References